NovAccess Global to Participate in LD Micro Invitational XII Conference
NovAccess Global to Participate in LD Micro Invitational XII Conference
CLEVELAND, OH / ACCESSWIRE / May 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin is scheduled to participate in the LD Micro Invitational XII Conference on June 7-9, 2022. The conference is being held at the Four Seasons Hotel Westlake Village near Los Angeles, CA. This will be an in-person conference with NovAccess Global presenting on Tuesday, June 7, 2022, at 4:00 pm pacific time in Track 4 and hosting 1:1 meetings with investors throughout the day.
俄亥俄州克利夫蘭/ACCESSWIRE/2022年5月19日/NovAccess Global Inc.(場外交易市場代碼：XSNX)宣佈，其首席執行官Dwain Irvin博士計劃參加2022年6月7日至9日舉行的第12屆LD Micro邀請賽。會議在加利福尼亞州洛杉磯附近的西湖村四季酒店舉行。這將是一次面對面的會議，NovAccess Global將於2022年6月7日(星期二)太平洋時間下午4：00在Track 4舉行會議，並全天主持與投資者的1：1會議。
Presentation materials will be made available on the morning of June 7 on the Investor Relations section of the Company's website. Investors interested in meeting with NovAccess Global should contact LD Micro or Jordan Darrow of Darrow Associates, IR for the Company, at jdarrow@darrowir.com.
演示材料將於6月7日上午在公司網站的投資者關係部分提供。有意與NovAccess全球公司會面的投資者請聯繫LD Micro或Darrow Associates公司的喬丹·達羅，電子郵件：jdarrow@darrowir.com。
NovAccess Global is a translational biotechnology company developing novel immunotherapies for brain tumor patients, featuring recently approved United States patent #US9764014B2. The patent is granted under the "Cancer Antigens" category and related to the "treatment of cancer using vaccination therapy." The Company is working on future milestones of getting uplisted on OTCQB, filing for orphan drug status, and filing for Phase IIa IND application with FDA.
NovAccess Global是一家為腦瘤患者開發新型免疫療法的翻譯生物技術公司，最近獲得批准的美國專利#US9764014B2。這項專利是在“癌症抗原”類別下授予的，與“使用疫苗療法治療癌症”有關。該公司正在制定未來的里程碑，包括在OTCQB上市，申請孤兒藥物地位，以及向FDA提交IIa期IND申請。
About NovAccess Global
關於NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.
NovAccess Global是一家加速新型癌症診斷和治療的生物醫藥公司。我們的目標是發現、開發和向市場推出新穎和創新的藥物和醫療設備，以提高癌症和神經科患者的護理質量。
NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. The Company owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.
NovAccess Global目前正在開發一種癌症疫苗療法，以增強患者對腦瘤的免疫反應。我們公司有一種新的免疫治療方法來治療患有多形性膠質母細胞瘤的腦腫瘤患者，多形性膠質母細胞瘤是最常見的成人腦腫瘤，確診後中位生存期為15個月。我們的專利技術旨在將基於樹突狀細胞的免疫治療方法與Toll-like Receptor(TLR)佐劑的獨特組合TLR-AD1相結合，以幫助促進針對患者腫瘤的增強免疫反應。我們的平臺技術專注於通過利用患者腫瘤特有的抗原來增強患者的免疫細胞，以對抗他們獨特的癌症。該公司擁有一種癌症疫苗，這是一種通過加強人體對癌細胞的天然防禦來刺激或恢復免疫系統對抗現有癌症的能力的藥物。這是一項有意義的技術，可以顯著提高許多腦瘤患者的生活質量和預後。欲瞭解更多信息，請訪問novacesslobal.com。
Forward-Looking Statement
前瞻性陳述
This email and its attachments contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission and/or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.
本電子郵件及其附件包含《1933年證券法》(經修訂)第27A節和《1934年證券交易法》(經修訂)第21E節所指的“前瞻性陳述”，此類前瞻性陳述是根據1995年“私人證券訴訟改革法”的安全港條款作出的。“前瞻性陳述”描述未來的預期、計劃、結果或戰略，通常以“可能”、“未來”、“計劃”或“計劃”、“將”或“應該”、“預期”、“預期”、“草案”、“最終”或“預計”等詞語開頭。請注意，此類陳述會受到大量風險和不確定性的影響，可能會導致未來的情況、事件或結果與前瞻性陳述中預測的情況、事件或結果大不相同，包括由於各種因素，實際結果可能與前瞻性陳述中預測的結果大不相同的風險，以及公司向證券交易委員會和/或場外交易市場公司提交的披露或文件中確定的其他風險。請進一步提醒您，細價股和NovAccess，Inc.等較小公司的股票本質上是不穩定和有風險的，除非投資者能夠承受全部投資的損失，否則投資者不應購買這種股票。公司沒有義務更新任何前瞻性陳述，以反映事件或情況發生之後的情況。
Investor Relations Contact:
投資者關係聯繫人：
Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com
喬丹·達羅
Darrow Associates
631-766-4528
郵箱：jdarrow@darrowir.com
SOURCE: NovAccess Global Inc.
資料來源：NovAccess Global Inc.
譯文內容由第三人軟體翻譯。